title: Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.
abstract: This study assessed the clinical performance of a combined PET/CT system using (18)F-FDG in oncologic patients.
  
  
  METHODS
  (18)F-FDG PET/CT was used to evaluate 204 patients with 586 suspicious lesions. All patients had available follow-up data, enabling assessment of the clinical significance of hybrid PET/CT findings. Differences in interpretation between PET, CT, and fused PET/CT data were prospectively documented for detection, localization, and characterization of each evaluated site. The additional value of PET/CT for data interpretation over that of separate PET and CT was classified into several criteria, including change in lesion characterization to either definitely benign or definitely malignant, precise anatomic localization of malignant (18)F-FDG uptake, and retrospective lesion detection on PET and CT. The clinical impact of information provided by PET/CT on patient management was assessed on the basis of follow-up data concerning further diagnostic or therapeutic approach. Analysis of data was performed for the whole study population, for different types of cancer, and for different anatomic sites.
  
  
  RESULTS
  PET/CT provided additional information over the separate interpretation of PET and CT in 99 patients (49%) with 178 sites (30%). PET/CT improved characterization of equivocal lesions as definitely benign in 10% of sites and as definitely malignant in 5% of sites. It precisely defined the anatomic location of malignant (18)F-FDG uptake in 6%, and it led to retrospective lesion detection on PET or CT in 8%. The results of PET/CT had an impact on the management of 28 patients (14%). Hybrid PET/CT data obviated the need for further evaluation in 5 patients, guided further diagnostic procedures in 7 patients, and assisted in planning therapy for 16 patients.
  
  
  CONCLUSIONS
  Hybrid PET/CT improves the diagnostic interpretation of (18)F-FDG PET and CT in cancer patients and has an impact on both diagnostic and therapeutic aspects of patient management.
authors.affiliation: Department of Nuclear Medicine, Rambam Medical Center, Haifa 35254, Israel.
authors.forename: Rachel
authors.initials: R
authors.lastname: Bar-Shalom
authors.forename: Nikolai
authors.initials: N
authors.lastname: Yefremov
authors.forename: Ludmila
authors.initials: L
authors.lastname: Guralnik
authors.forename: Diana
authors.initials: D
authors.lastname: Gaitini
authors.forename: Alex
authors.initials: A
authors.lastname: Frenkel
authors.forename: Abraham
authors.initials: A
authors.lastname: Kuten
authors.forename: Hernan
authors.initials: H
authors.lastname: Altman
authors.forename: Zohar
authors.initials: Z
authors.lastname: Keidar
authors.forename: Ora
authors.initials: O
authors.lastname: Israel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging*; D011786:Quality Control; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013382:Subtraction Technique; D014055:Tomography, Emission-Computed / Q000379:methods*; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18